SCAAR

SCAAR Registry

Clinical Study

Swedish Coronary Angiography and Angioplasty Registry

Downloads

Conclusion

  • Orsiro showed the lowest event rate1 of all DES out to five years2
  • The main competitors3 have not yet reached such long follow-up and show higher event rates for the follow-up time after index procedure
  • These convincing results in a real world setting reconfirm those of previous Orsiro clinical studies and add to the solid foundation of clinical evidence that supports the use of Orsiro across a broad range of applications

Study Design

Large all-comers registry recordingall PCI procedures from all 29 centers in Sweden since May 1, 2005Endpoint: Registration of occlusions with acute clinical presentation

Results5

All stents implanted from 2007 until January 11, 2017 unadjusted

Orsiro Image

Vascular Intervention

Orsiro

Drug-Eluting Stent

Orsiro Image

Vascular Intervention

ORIENT

Clinical Study

1 Event rate is the cumulative rate of restenosis which includes acute stent occlusion or non-occlusive thrombus.

3 Xience Xpedition, Resolute Onyx and Synergy

5 Adapted from SCAAR (http://www.ucr.uu.se/swedeheart/component/ifaq/article/167-stent-reports/652-restenosis-in-stents 2007-to-january-11th-2017).

2 Compared to other DES at five years.

4 Synergy is a registered trademark of Boston Scientific, Resolute and Resolute Onyx are registered trademarks of Medtronic Vascular, Xience and Xience Xpedition are registered trademarks of Abbott Cardiovascular Systems